Notably, UC-514321 treatment cured 66.7% (4 out of 6) of the MLL-AF9 AML mice (Fig. 4f, j), and none of the UC-514321-treated FLT3-ITD/NPM1mut AML recipients developed full-blown AML within 50 days (Fig. 4i). This evidence concerns the gene KMT2A and acute myeloid leukemia.